CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Mogamulizumab (KW-0761)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02281409
NCT02281409Phase 2Completed
CompareCT.gov

A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Memorial Sloan Kettering Cancer Center·interventional·Posted Nov 3, 2014·Updated Apr 23, 2021

In Brief

A Phase 2 clinical trial evaluating Mogamulizumab (KW-0761) for Advanced Solid Tumors and Metastatic Solid Tumors. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of this study is to find out what effects, good and/or bad, KW-0761, an investigational drug, has on the patient and their cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Metastatic Solid Tumors
CountriesUnited States
CollaboratorsKyowa Hakko Kirin Pharma, Inc.

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 3, 2014
Enrollment StartOct 1, 2014
Primary CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 11.7 years ago

Interventions

Mogamulizumab (KW-0761)biological